Intermediate monocytes in ANCA vasculitis: increased surface expression of ANCA autoantigens and IL-1 beta secretion in response to anti-MPO antibodiesO'Brien, E. C., Abdulahad, W. H., Rutgers, A., Huitema, M. G., O'Reilly, V. P., Coughlan, A. M., Harrington, M., Heeringa, P., Little, M. A. & Hickey, F. B., 7-Jul-2015, In : Scientific Reports. 5, 12 p., 11888.
Research output: Contribution to journal › Article › Academic › peer-review
ANCA vasculitis encompasses several autoimmune conditions characterised by destruction of small vessels, inflammation of the respiratory tract and glomerulonephritis. Most patients harbour autoantibodies to myeloperoxidase (MPO) or proteinase 3 (PR3). Clinical and experimental data suggest that pathogenesis is driven by ANCA-mediated activation of neutrophils and monocytes. We investigated a potential role for distinct monocyte subsets. We found that the relative proportion of intermediate monocytes is increased in patients versus control individuals, and both MPO and PR3 are preferentially expressed on these cells. We demonstrate that MPO and PR3 are expressed independently of each other on monocytes and that PR3 is not associated with CD177. MPO expression correlates with that of Fc receptor CD16 on intermediate monocytes. Monocyte subsets respond differently to antibodies directed against MPO and PR3, with anti-MPO but not anti-PR3 leading to increased IL-1 beta, IL-6 and IL-8 production. In concordance with the observed higher surface expression of MPO on intermediate monocytes, this subset produces the highest quantity of IL-1 beta in response to anti-MPO stimulation. These data suggest that monocytes, specifically, the intermediate subset, may play a role in ANCA vasculitis, and also indicate that substantial differences exist between the effect of anti-MPO and anti-PR3 antibodies on these cells.
|Number of pages||12|
|Publication status||Published - 7-Jul-2015|
- ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES, BLOOD MONOCYTES, CRESCENTIC GLOMERULONEPHRITIS, WEGENERS-GRANULOMATOSIS, ANTIPROTEINASE 3, CELL ACTIVATION, PROTEINASE-3, SPECIFICITY, RELEASE, NOMENCLATURE